학술논문

Overall survival and updated progression-free survival outcomes in a randomized phase II study of combination cediranib and olaparib versus olaparib in relapsed platinum-sensitive ovarian cancer
Document Type
Article
Source
In Annals of Oncology April 2019 30(4):551-557
Subject
Language
ISSN
0923-7534